|
TSIIC Allocates 20 Acres Land To Set Up Cardiac Stent
Manufacturing Unit At Medical Devices Park In Telangana
The Telangana State Industrial and Infrastructure Corporation (TSIIC) has
allocated 20 acres of land to set up Asia’s largest cardiac stent manufacturing
plant at medical devices park located at Sultanpur in Sangareddy district of
Telangana.
As part of this programme, Indian medical device company, Sahajanand Medical
Technologies (SMT) has come forward to invest Rs. 250 crore to set up the unit.
SMT is India’s second leading provider of cardiac stents in the country and
abroad.
During the inaugural ceremony of the programme, Telangana health minister said,
Telangana state government is committed to make the state a hub for pharma,
biotechnology and medical devices sectors in the country.
“Already Telangana is known for its bulk drugs, formulations and vaccine
manufacturing industries in the country. Now we have decided to make Telangana
the medical devices manufacturing hub and had long back established a special
economic zone (SEZ) for the same.
With this new investment, SMT will set up its state of the art southern regional
manufacturing campus which is expected to manufacture 1.25 million cardiac
stents per annum from this unit.
http://pharmabiz.com/NewsDetails.aspx?aid=117952&sid=1
Medical Devices Exporter Poly Medicure Eyes 17-18% Revenue
Growth
The New Delhi-based Poly Medicure Limited, one of the leading manufacturer and
exporter of medical devices, is eyeing 17-18% revenue growth for the next
financial year 2019-20.
The company is expanding its manufacturing footprint by investing in capacity
expansion to meet new demand over the next few years.
On expansion, Himanshu Baid, MD, Poly Medicure said, "We are setting up a new
plant at Mahindra Special Economic Zone (SEZ) in Jaipur and also doing phase 2
expansion of IMT Faridabad plant. Besides, we are doing further capacity
expansion in the existing plants in Faridabad. We have registered growth in most
of our key markets and hope to continue this momentum with a sharper focus on
innovation. We will also focus on US and European markets in near future and
will be expanding our reach in Africa”.
The company is also planning to launch new products in core therapy areas in
vascular access, infusion therapy accessories, dialysis, blood management and
diagnostic in near future. With its strong research and development (R&D)
initiatives, the company has been granted 230 plus product and process patents
globally and has also filed for grant of an additional 210 plus patents.
http://pharmabiz.com/NewsDetails.aspx?aid=118074&sid=1 |
